Tramadol Hydrochloride Tablet, Coated
Product Images NDC 87441-089

4 FDA label images from Unit Dose Solutions, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 87441-089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tramadol 50mg (8744108901 Tramadol 50 mg)

Tramadol 50mg (8744108901 Tramadol 50 mg)
Tramadol Hydrochloride 50 mg coated tablets label for oral administration. The label indicates prescription use only, with directions for pharmacists to dispense a Medication Guide. It includes storage information and cautions about keeping the product out of reach of children. Repackaged by Unit Dose Solutions, Inc. and distributed by Tuckahoe Enterprises, LLC.*
FDA Label Image

1 (Tramadol Hydrochloride Tablets Usp 50 mg 1)

1 (Tramadol Hydrochloride Tablets Usp 50 mg 1)
Chemical structure diagram of Tramadol Hydrochloride showing its molecular composition including functional groups and the HCl moiety.*
FDA Label Image

1 (Tramadol Hydrochloride Tablets Usp 50 mg 2)

1 (Tramadol Hydrochloride Tablets Usp 50 mg 2)
A pharmacokinetic concentration-time graph depicting Tramadol and its metabolite M1 levels in ng/mL over 48 hours following single and multiple doses. The graph shows higher concentrations and prolonged presence for multiple doses compared to single dose for both Tramadol and M1.*
FDA Label Image

1 (Tramadol Hydrochloride Tablets Usp 50 mg 3)

1 (Tramadol Hydrochloride Tablets Usp 50 mg 3)
A line graph titled 'Protocol CAPSS-047 Time to Discontinuation Due to Nausea/Vomiting' showing percent discontinuing over days in double-blind phase. Two lines represent different dosing durations: 10 days to 200 mg/day and 16 days to 200 mg/day. The graph plots percent discontinuing on the Y-axis and days on the X-axis, illustrating higher discontinuation for the 10-day dosing.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.